Biopharmaceutical company
Appears in 1 story
Developer of HBI-8000; plans to share Phase 3 data with the FDA
A twice-weekly pill that strips melanoma cells of their camouflage extended progression-free survival by more than four months when added to the standard immunotherapy nivolumab. The Phase 3 result, presented at the European Society for Medical Oncology (ESMO) congress in Madrid, cut the risk of disease progression or death by 27%.
Updated 2 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
